A biomarker-enriched, randomized phase II trial of Adavosertib (AZD1775) plus Paclitaxel and Carboplatin for women with Platinum-sensitive TP53-mutant Ovarian Cancer - Oza, Amit M.; Estevez-Diz, Maria; Grischke, Eva-Maria; Hall, Marcia; Marmé, Frederik; Provencher, Diane; Uyar, Denise; Weberpals, Johanne I.; Wenham, Robert M.; Laing, Naomi; Tracy, Michael; Freshwater, Tomoko; et al. (Clinical cancer research, 2020)
Gesehen am 26.09.2025